Skip to main content

NIMBUS trial

In the phase 3 NIMBUS trial, patients with high-grade non-muscle invasive bladder carcinoma were randomly assigned to receive either the standard or a reduced number of Bacillus Calmette-Guérin doses with a view to establish the noninferiority of the reduced number of infusions.

Results presented at ASCO GU 2020 showed that the standard dose is superior:

Read transcript

Related content

16-02-2020 | ASCO GU 2020 | Conference coverage | Video

Expert highlights from ASCO GU 2020

Image Credits